When organizations outsource everything, they lose the institutional knowledge and strategic control needed to make critical development decisions.
Full Outsourcing Leads to Loss of Control.
One Idea Worth Acting On.
A biotech hands an entire pivotal oncology trial to a major CRO to maximize efficiency and reduce overhead.
One year later: enrollment is stalled, timelines are slipping, budgets have exploded, and data quality concerns now threaten the regulatory filing.
The sponsor blames the vendor.
The real failure was never the CRO's execution. It was the sponsor's abdication of accountability.
When internal teams are stretched, full outsourcing feels like a solution. The CRO manages the sites, runs the trial, delivers the data, and hands back a regulatory package. The sponsor gets the output without the operational burden.
Except oncology trials are not assembly lines. They are dynamic, high-stakes scientific systems that require constant judgment, adaptation, and oversight.
Unexpected safety signals emerge. Enrollment patterns shift. Protocol deviations accumulate. Operational decisions rapidly affect scientific integrity. When the sponsor has disengaged from those realities, minor problems compound into systemic failures — and by the time leadership recognizes the damage, timelines and budgets are already deeply compromised.
The problem is not outsourcing. It is the assumption that outsourcing the execution also outsources the accountability. It does not. The CRO does not own the molecule. It does not carry the scientific, regulatory, financial, or reputational risk the sponsor carries. It cannot make the judgment calls that only the sponsor can make.
When organizations fully outsource their pipeline execution, they slowly surrender institutional knowledge about their own asset. The team that should be building deep expertise in the molecule's behavior across patient populations is instead reviewing reports from a vendor who is managing fifteen other programs simultaneously.
That knowledge gap does not close after the trial ends. It follows the asset into the regulatory filing, the launch, and the post-approval lifecycle — at every stage where the organization needs to defend decisions it was not present to make.
A lean biotech outsources a Phase 3 program and reduces direct oversight to monthly steering committee calls. Enrollment starts slowly at key sites. The CRO flags it as a site performance issue and activates backup sites.
Six months later the backup sites have introduced a patient population that differs meaningfully from the primary sites — different prior treatment history, different performance status distribution. The difference is not large enough to fail the trial. It is large enough to complicate the subgroup analysis the payer dossier depends on.
The sponsor did not make that decision. The sponsor did not know that decision was being made. Full outsourcing created the condition for it. As Dr. Roy Baynes, veteran Clinical Development leader and contributor to Voices of Oncology, describes it: programmatically outsourced trials historically produce severe cost overruns, major delays, and critical quality failures. Not because CROs are incapable. Because once the sponsor disconnects from operational reality, strategic alignment begins to weaken, communication fragments, and scientific nuance gets diluted.
Outsourcing operational execution is legitimate and often necessary. Outsourcing scientific accountability is not.
The sponsor needs named internal ownership of every major trial decision — not as oversight bureaucracy but as genuine scientific stewardship. Someone inside the organization who understands the molecule, knows the patients, and has the authority to redirect the CRO when the trial requires it.
The organizations that run the most successful outsourced programs are not the ones that hand off and step back. They are the ones that stay close to the science while delegating the operations.
A CRO can run your trial. It cannot own your molecule.
The moment a sponsor forgets that distinction is the moment the trial starts running without the judgment it needs.
Add Your Voice — Where are you seeing this? What's working — and what's not?
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
iNIZIO
iNIZIO
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Michael Pietrack